Metsera Inc. (NASDAQ:MTSR - Get Free Report)'s share price shot up 6.3% during trading on Wednesday . The stock traded as high as $32.18 and last traded at $32.01. 118,997 shares were traded during trading, a decline of 87% from the average session volume of 903,129 shares. The stock had previously closed at $30.12.
Analyst Upgrades and Downgrades
Several research firms have recently commented on MTSR. Wells Fargo & Company began coverage on shares of Metsera in a research report on Friday, June 20th. They set an "overweight" rating and a $65.00 price target for the company. Guggenheim upped their price target on shares of Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a research report on Tuesday, June 10th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $55.00.
Check Out Our Latest Report on Metsera
Metsera Stock Performance
The stock's 50-day moving average price is $28.54.
Metsera (NASDAQ:MTSR - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($1.03) earnings per share (EPS) for the quarter.
Institutional Investors Weigh In On Metsera
A number of institutional investors and hedge funds have recently bought and sold shares of MTSR. Bank of New York Mellon Corp acquired a new stake in Metsera in the 1st quarter valued at about $884,000. New York State Common Retirement Fund acquired a new stake in Metsera in the 1st quarter valued at about $131,000. Alphabet Inc. acquired a new stake in Metsera in the 1st quarter valued at about $135,059,000. Massachusetts Financial Services Co. MA acquired a new stake in Metsera in the 1st quarter valued at about $13,111,000. Finally, Jennison Associates LLC acquired a new stake in Metsera in the 1st quarter valued at about $9,679,000.
Metsera Company Profile
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
See Also
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
